within Pharmacolibrary.Drugs.ATC.A;

model A16AX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.165,
    Cl             = 15.3 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.0088,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007733333333333333,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Sapropterin dihydrochloride is a synthetic form of tetrahydrobiopterin (BH4), a natural cofactor for the enzyme phenylalanine hydroxylase. It is used as an adjunct treatment for phenylketonuria (PKU) in both pediatric and adult patients who have been shown to be responsive to this therapy. Sapropterin is an FDA- and EMA-approved medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following a single oral dose (10 mg/kg) in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Feillet, F, et al., &amp; Foehr, E (2008). Pharmacokinetics of sapropterin in patients with phenylketonuria. <i>Clinical pharmacokinetics</i> 47(12) 817–825. DOI:<a href=&quot;https://doi.org/10.2165/0003088-200847120-00006&quot;>10.2165/0003088-200847120-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19026037/&quot;>https://pubmed.ncbi.nlm.nih.gov/19026037</a></p></li><li><p>Muntau, AC, et al., &amp; Rogoff, D (2017). Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients &lt;4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial. <i>Orphanet journal of rare diseases</i> 12(1) 47–None. DOI:<a href=&quot;https://doi.org/10.1186/s13023-017-0600-x&quot;>10.1186/s13023-017-0600-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28274234/&quot;>https://pubmed.ncbi.nlm.nih.gov/28274234</a></p></li><li><p>Sanford, M, &amp; Keating, GM (2009). Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia. <i>Drugs</i> 69(4) 461–476. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200969040-00006&quot;>10.2165/00003495-200969040-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19323589/&quot;>https://pubmed.ncbi.nlm.nih.gov/19323589</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AX07;
